Payment overview · 2025
General Payments
$79.18
3 reported records · 3 companies
Healthcare provider profile · identity verified
Ever Ivan Ponciano, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HAGERSTOWN, MD · NPI 1750572012
Verified facts
What the public records show
CMS Open Payments records show Ever Ivan Ponciano, M.D. received $79.18 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.90 | 40.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.49 | 36.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.79 | 23.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.18 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
79 | 79 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
120 | 85 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 325 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 253 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 243 | 78 |
| Lisinopril | Lisinopril | 235 | 77 |
| Omeprazole | Omeprazole | 200 | 72 |
| Losartan Potassium | Losartan Potassium | 191 | 61 |
| Gabapentin | Gabapentin | 184 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 74 |
| Montelukast Sodium | Montelukast Sodium | 172 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 55 |
| Lorazepam | Lorazepam | 147 | 55 |
| Azithromycin | Azithromycin | 138 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 42 |
| Simvastatin | Simvastatin | 131 | 43 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 120 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 110 | 24 |
| Famotidine | Famotidine | 108 | 36 |
| Furosemide | Furosemide | 107 | 40 |
| Sertraline Hcl | Sertraline Hcl | 107 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 38 |
| Tramadol Hcl | Tramadol Hcl | 92 | 41 |
| Alprazolam | Alprazolam | 88 | 23 |
| Trazodone Hcl | Trazodone Hcl | 88 | 30 |
| Metformin Hcl | Metformin Hcl | 85 | 35 |
| Potassium Chloride | Potassium Chloride | 84 | 30 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 79 | 79 |
| Prednisone | Prednisone | 77 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 21 |
| Pregabalin | Pregabalin | 75 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 15 |
| Eliquis | Apixaban | 71 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 24 |
| Clonazepam | Clonazepam | 67 | 16 |
| Methylprednisolone | Methylprednisolone | 65 | 59 |
| Valsartan | Valsartan | 64 | 21 |
| Mounjaro | Tirzepatide | 63 | 17 |
| Spironolactone | Spironolactone | 61 | 18 |
| Meloxicam | Meloxicam | 60 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 23 |
| Allopurinol | Allopurinol | 59 | 18 |
| Clonidine Hcl | Clonidine Hcl | 58 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 22 |
| Atenolol | Atenolol | 56 | 18 |
| Mirtazapine | Mirtazapine | 55 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 16 |
| Diazepam | Diazepam | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Finasteride | Finasteride | 43 | 11 |
| Temazepam | Temazepam | 42 | suppressed |
| Estradiol | Estradiol | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 20 |
| Trulicity | Dulaglutide | 40 | 14 |
| Carvedilol | Carvedilol | 39 | 16 |
| Ozempic | Semaglutide | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 32 |
| Fluconazole | Fluconazole | 38 | 23 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Metolazone | Metolazone | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 34 | 11 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 32 | 32 |
| Metformin Hcl Er | Metformin Hcl | 32 | 13 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 31 | 31 |
| Alendronate Sodium | Alendronate Sodium | 31 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | 12 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 18 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 23 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Methocarbamol | Methocarbamol | 18 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 12 |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Colchicine | Colchicine | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 15 |
| Cefdinir | Cefdinir | 15 | 12 |
| Cephalexin | Cephalexin | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.18 · 3 records | Novo Nordisk Inc | AREXVY, JARDIANCE, Ozempic, Rybelsus, SHINGRIX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error